Log in to search using one of your social media accounts:

 

Design and Implementation of a Novel Advanced Training Curriculum in Hemoglobinopathies
(Source: American Journal of Hematology)
Source: American Journal of Hematology - December 11, 2017 Category: Hematology Authors: Richard Ward Tags: Correspondence Source Type: research

No Major Differences in Outcomes Between the Initial and Relapse Episodes in Patients with Thrombotic Thrombocytopenic Purpura: The Experience from the Ohio State University Registry
(Source: American Journal of Hematology)
Source: American Journal of Hematology - December 11, 2017 Category: Hematology Authors: Camila Masias, Haiwa Wu, Michael McGookey, Lauren Jay, Spero Cataland, Shangbin Yang Tags: Correspondence Source Type: research

Age is the only predictor of small decrease in lung function in children with sickle cell anemia
This article is protected by copyright. All rights reserved. (Source: American Journal of Hematology)
Source: American Journal of Hematology - December 11, 2017 Category: Hematology Authors: Shaina M. Willen, Robyn Cohen, Mark Rodeghier, Fenella Kirkham, Susan S. Redline, Carol Rosen, Jane Kirkby, Michael R. DeBaun Tags: Research Article Source Type: research

Pure erythroid leukemia
(Source: American Journal of Hematology)
Source: American Journal of Hematology - December 11, 2017 Category: Hematology Authors: Barbara J. Bain Tags: Correspondence Source Type: research

Similar outcome of allogeneic stem cell transplantation after myeloablative and sequential conditioning regimen in patients with refractory or relapsed acute myeloid leukemia: A study from the Soci été Francophone de Greffe de Moelle et de Thérapie Cellulaire
Abstract Patients with acute myeloid leukemia (AML) in relapse or refractory to induction therapy have a dismal prognosis. Allogeneic hematopoietic stem cell transplantation is the only curative option. In these patients, we aimed to compare the results of a myeloablative transplant versus a sequential approach consisting in a cytoreductive chemotherapy followed by a reduced intensity conditioning regimen and prophylactic donor lymphocytes infusions. We retrospectively analyzed 99 patients aged 18‐50 years, transplanted for a refractory (52%) or a relapsed AML not in remission (48%). Fifty‐eight patients received a seq...
Source: American Journal of Hematology - December 11, 2017 Category: Hematology Authors: Justine Decroocq, Rapha ël Itzykson, Stéphane Vigouroux, Mauricette Michallet, Ibrahim Yakoub‐Agha, Anne Huynh, Florence Beckerich, Felipe Suarez, Patrice Chevallier, Stéphanie Nguyen‐Quoc, Marie‐Pierre Ledoux, Laurence Clement, Yosr Hicheri, Ga Tags: Research Article Source Type: research

Comparing Apples to Oranges: A commentary on the Mayo study of MYD88 significance in Waldenstrom's Macroglobulinemia
(Source: American Journal of Hematology)
Source: American Journal of Hematology - December 8, 2017 Category: Hematology Authors: Jorge J. Castillo, Joshua N. Gustine, Kirsten Meid, Lian Xu, Zachary R. Hunter, Steven P. Treon Tags: Correspondence Source Type: research

Successful liver transplantation for homozygous protein C deficiency with a Type II mutation using a heterozygous living related donor
(Source: American Journal of Hematology)
Source: American Journal of Hematology - December 8, 2017 Category: Hematology Authors: Alexander A. Boucher, Lori Luchtman ‐Jones, Jaimie D. Nathan, Joseph S. Palumbo Tags: Solving Clinical Problems in Blood Diseases Source Type: research

Clinical Experience with the BCL2 ‐inhibitor Venetoclax in Combination Therapy for Relapsed and Refractory Acute Myeloid Leukemia and Related Myeloid Malignancies
Conclusion: Low‐intensity chemotherapy, i.e. HMAs or LDAC, in combination with VEN is a viable salvage option, even in multiply relapsed/refractory patients with AML, MDS, and BPDCN. Notable responses were identified in patients with diploid/intermediate cytogenetics, RUNX1 and/or IDH1/2 mutations. This article is protected by copyright. All rights reserved. (Source: American Journal of Hematology)
Source: American Journal of Hematology - December 8, 2017 Category: Hematology Authors: Courtney D DiNardo, Caitlin R Rausch, Christopher Benton, Tapan Kadia, Nitin Jain, Naveen Pemmaraju, Naval Daver, Wendy Covert, Kayleigh R Marx, Morgan Mace, Elias Jabbour, Jorge Cortes, Guillermo Garcia ‐Manero, Farhad Ravandi, Kapil N Bhalla, Hagop Ka Tags: Research Article Source Type: research

Myelodysplastic syndromes: 2018 update on diagnosis, risk ‐stratification and management
Abstract Disease overviewThe myelodysplastic syndromes (MDS) are a very heterogeneous group of myeloid disorders characterized by peripheral blood cytopenias and increased risk of transformation to acute myelogenous leukemia (AML). MDS occurs more frequently in older males and in individuals with prior exposure to cytotoxic therapy. DiagnosisDiagnosis of MDS is based on morphological evidence of dysplasia upon visual examination of a bone marrow aspirate and biopsy. Information obtained from additional studies such as karyotype, flow cytometry or molecular genetics is usually complementary and may help refine diagnosis. Ri...
Source: American Journal of Hematology - December 7, 2017 Category: Hematology Authors: Guillermo Montalban ‐Bravo, Guillermo Garcia‐Manero Tags: ANNUAL CLINICAL UPDATES IN HEMATOLOGICAL MALIGNANCIES Source Type: research

Issue information – table of contents
(Source: American Journal of Hematology)
Source: American Journal of Hematology - December 7, 2017 Category: Hematology Tags: ISSUE INFORMATION – TABLE OF CONTENTS Source Type: research

Laboratory tests for identification or exclusion of heparin induced thrombocytopenia: HIT or miss?
Abstract Heparin induced thrombocytopenia (HIT) is a potentially fatal condition that arises subsequent to formation of antibodies against complexes containing heparin, usually platelet‐factor 4‐heparin (“anti‐PF4‐heparin”). Assessment for HIT involves both clinical evaluation and, if indicated, laboratory testing for confirmation or exclusion, typically using an initial immunological assay (“screening”), and only if positive, a secondary functional assay for confirmation. Many different immunological and functional assays have been developed. The most common contemporary immunological assay...
Source: American Journal of Hematology - December 6, 2017 Category: Hematology Authors: Emmanuel J. Favaloro Tags: TEST OF THE MONTH Source Type: research

Hereditary xerocytosis: Diagnostic considerations
(Source: American Journal of Hematology)
Source: American Journal of Hematology - December 1, 2017 Category: Hematology Authors: Mary Risinger, Edyta Glogowska, Satheesh Chonat, Kejian Zhang, Neha Dagaonkar, Clinton H. Joiner, Charles T. Quinn, Theodosia A. Kalfa, Patrick G. Gallagher Tags: Correspondence Source Type: research

Comprehensive Management Reduces Incidence and Mortality of Acute Chest Syndrome in Patients with Sickle Cell Disease
(Source: American Journal of Hematology)
Source: American Journal of Hematology - December 1, 2017 Category: Hematology Authors: Givi Basishvili, Joseph Gotesman, Kathy Vandervoort, Charleen Jacobs, Leena Vattappally, Caterina P. Minniti Tags: Correspondence Source Type: research

Macrophage activation syndrome and post ‐transplant microangiopathy following haploidentical bone marrow transplantation for sickle cell anemia
(Source: American Journal of Hematology)
Source: American Journal of Hematology - December 1, 2017 Category: Hematology Authors: James O. J. Davies, Alice C. Hart, Josu De La Fuente, Barbara J. Bain Tags: Morphology Update Source Type: research

“Double‐hit” chronic lymphocytic leukemia: An aggressive subgroup with 17p deletion and 8q24 gain
This article is protected by copyright. All rights reserved. (Source: American Journal of Hematology)
Source: American Journal of Hematology - December 1, 2017 Category: Hematology Authors: Elise Chapiro, Claude Lesty, Cl émentine Gabillaud, Eric Durot, Simon Bouzy, Marine Armand, Magali Le Garff‐Tavernier, Nadia Bougacha, Stéphanie Struski, Audrey Bidet, Elodie Laharanne, Carole Barin, Lauren Veronese, Nolwen Prié, Virginie Eclache, Ba Tags: Research Article Source Type: research

The role of tmprss6 and hfe variants in iron deficiency anemia in celiac disease
Abstract We investigated the role of HFE C282Y, H63D and TMPRSS6 A736V variants in the pathogenesis of iron deficiency anemia (IDA) in celiac disease (CD) patients, at diagnosis and after 1‐year of gluten free diet (GFD). Demographic and clinical features were prospectively recorded for all CD patients between 2013 and 2017. C282Y, H63D and A736V variants were evaluated for CD patients and controls. Finally, 505 consecutive CD patients and 539 age‐matched control subjects were enrolled. At diagnosis, 229 CD subjects had IDA (45.3%), with a subgroup of anemic patients (45.4%) presented persistent IDA at follow‐up. C28...
Source: American Journal of Hematology - December 1, 2017 Category: Hematology Authors: Luigia De Falco, Raffaella Tortora, Nicola Imperatore, Mariasole Bruno, Mario Capasso, Domenico Girelli, Annalisa Castagna, Nicola Caporaso, Achille Iolascon, Antonio Rispo Tags: Research Article Source Type: research

Survival Following Salvage Therapy for Primary Refractory Peripheral T ‐Cell Lymphomas (PTCL)
This article is protected by copyright. All rights reserved. (Source: American Journal of Hematology)
Source: American Journal of Hematology - December 1, 2017 Category: Hematology Authors: Janie Y. Zhang, Robert Briski, Sumana Devata, Mark S. Kaminski, Tycel J. Phillips, Tera L. Mayer, Nathanael G. Bailey, Ryan A. Wilcox Tags: Research Article Source Type: research

Splanchnic vein thrombosis in patients with myeloproliferative neoplasms: The Mayo Clinic experience with 84 consecutive cases
(Source: American Journal of Hematology)
Source: American Journal of Hematology - December 1, 2017 Category: Hematology Authors: Sravanthi Lavu, Natasha Szuber, Mythri Mudireddy, Meera Yogarajah, Naseema Gangat, Animesh Pardanani, Curtis A. Hanson, Rhett P. Ketterling, Aneel A. Ashrani, Patrick S. Kamath, Ayalew Tefferi Tags: Correspondence Source Type: research

Anthracycline ‐induced acute myocarditis and ventricular fibrillation arrest
(Source: American Journal of Hematology)
Source: American Journal of Hematology - December 1, 2017 Category: Hematology Authors: Vincent A. Pallazola, Joseph C. Murray, Munjid Al Harthy, Stefan L. Zimmerman, Jonathan Webster, Lukasz P. Gondek Tags: Diagnostic Imaging in Hematology Source Type: research

Outcome of Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia after Blinatumomab Failure: No Change in the Level of CD19 Expression
This article is protected by copyright. All rights reserved. (Source: American Journal of Hematology)
Source: American Journal of Hematology - November 27, 2017 Category: Hematology Authors: Elias Jabbour, Johannes D üll, Musa Yilmaz, Joseph D. Khoury, Farhad Ravandi, Nitin Jain, Hermann Einsele, Guillermo Garcia‐Manero, Marina Konopleva, Nicholas J. Short, Philip A. Thompson, William Wierda, Naval Daver, Jorge Cortes, Susan O'Brien, Hagop Tags: Research Article Source Type: research

Hereditary hypochromic microcytic anemia associated with loss ‐of‐function DMT1 gene mutations and absence of liver iron overload
(Source: American Journal of Hematology)
Source: American Journal of Hematology - November 27, 2017 Category: Hematology Authors: Maddalena Casale, Adriana Borriello, Saverio Scianguetta, Domenico Roberti, Martina Caiazza, Debora Bencivenga, Immacolata Tartaglione, Saverio Ladogana, Matteo Maruzzi, Fulvio Della Ragione, Silverio Perrotta Tags: Correspondence Source Type: research

Visualization of the bone marrow biopsy needle track
(Source: American Journal of Hematology)
Source: American Journal of Hematology - November 23, 2017 Category: Hematology Authors: Shirin Attarian, Louis Reed, Shashi Singh, Alexander Shestopalov, Aditi P Singh, Anjali Budhathoki, Simon Abi ‐Aad, Urvi Shah, Salem Kim, Kimo Bachiashvili, Tarek Elrafei, Weijuan Li, Conway Yee, Ellen Friedman Tags: Correspondence Source Type: research

Bendamustine plus rituximab for indolent B ‐cell lymphoma of renal significance
Abstract Treatment of indolent B‐cell non‐Hodgkin lymphomas (iNHL) of renal significance is challenging given the need for deep and prolonged hematological response to restore and control renal function overtime, yet to be balanced with the risk of adverse drug‐related events. This prospective single‐center study included 20 patients with iNHL of renal significance (tubulointerstitial presentation [n=8], glomerulopathy with or without monoclonal Ig deposits [n=12]) who received a steroid‐sparing regimen of rituximab plus bendamustine (BR), with either no or
Source: American Journal of Hematology - November 23, 2017 Category: Hematology Authors: David Ribes, H élène El Hachem, Lucie Oberic, François Vergez, Audrey Delas, Julie Belliere, Caroline Protin, Nassim Kamar, Inès Ferrandiz, Suzanne Tavitian, Camille Laurent, Antoine Huart, Dominique Chauveau, Loïc Ysebaert, Stanislas Faguer Tags: Research Article Source Type: research

The clinical epidemiology of sickle cell anemia in Africa
Abstract Sickle cell anemia (SCA) is the commonest severe monogenic disorders of humans. The disease has been highly characterized in high‐income countries but not in sub‐Saharan Africa where SCA is most prevalent. We conducted a retrospective cohort study of all children 0‐13 years admitted from within a defined study area to Kilifi County Hospital in Kenya over a five‐year period. Children were genotyped for SCA retrospectively and incidence rates calculated with reference to population data. Overall, 576 of 18,873 (3.1%) admissions had SCA of whom the majority (399; 69.3%) were previously undiagnosed. The incide...
Source: American Journal of Hematology - November 23, 2017 Category: Hematology Authors: Alex W Macharia, George Mochamah, Sophie Uyoga, Carolyne M Ndila, Gideon Nyutu, Johnstone Makale, Metrine Tendwa, Emily Nyatichi, John Ojal, Mohammed Shebe, Kennedy O Awuondo, Neema Mturi, Norbert Peshu, Benjamin Tsofa, J Anthony G Scott, Kathryn Maitland Tags: Research Article Source Type: research

Secondary Acute Myeloid Leukaemia In Elderly patients: Patient's Fitness Criteria and ELN Prognostic Stratification Can Be Applied to Guide Treatment Decisions. An analysis of 280 Patients by the Network Rete Ematologica Lombarda (REL)
(Source: American Journal of Hematology)
Source: American Journal of Hematology - November 22, 2017 Category: Hematology Authors: Erika Borlenghi, Chiara Pagani, Patrizia Zappasodi, Massimo Bernardi, Claudia Basilico, Elisabetta Todisco, Nicola Fracchiolla, Valentina Mancini, Mauro Turrini, Matteo Da Vi à, Elisa Sala, Chiara Cattaneo, Marta Petullà, Federico Serana, Andrea Ferrari Tags: Correspondence Source Type: research

Driver mutations and prognosis in primary myelofibrosis: Mayo ‐Careggi MPN alliance study of 1,095 patients
Abstract The 2013 discovery of calreticulin (CALR) mutations in myeloproliferative neoplasms was attended by their association with longer survival in primary myelofibrosis (PMF). Subsequent studies have suggested prognostic distinction between type 1/like and type 2/like CALR mutations and detrimental effect from triple‐negative mutational status. Among 709 Mayo Clinic patients with PMF, 467 (66%) harbored JAK2, 112 (16%) CALR type 1/like, 24 (3.4%) CALR type 2/like, 38 (5.4%) MPL mutations and 68 (10%) were triple‐negative. Survival was longer with type 1/like CALR, compared to JAK2 (HR 2.6, 95% CI 1.9‐3.5), type 2...
Source: American Journal of Hematology - November 22, 2017 Category: Hematology Authors: Ayalew Tefferi, Maura Nicolosi, Mythri Mudireddy, Natasha Szuber, Christy M. Finke, Terra L. Lasho, Curtis A. Hanson, Rhett P. Ketterling, Animesh Pardanani, Naseema Gangat, Carmela Mannarelli, Tiziana Fanelli, Paola Guglielmelli, Alessandro M. Vannucchi Tags: Research Article Source Type: research

Laboratory tests for identification or exclusion of heparin induced thrombocytopenia ‐ HIT or miss?
This article is protected by copyright. All rights reserved. (Source: American Journal of Hematology)
Source: American Journal of Hematology - November 22, 2017 Category: Hematology Authors: Emmanuel J Favaloro Tags: Test of the Month Source Type: research

Intergroup LEAP Trial (S1612): A Randomized Phase 2/3 Platform Trial to Test Novel Therapeutics in Medically Less Fit Older Adults with Acute Myeloid Leukemia
(Source: American Journal of Hematology)
Source: American Journal of Hematology - November 22, 2017 Category: Hematology Authors: Roland B. Walter, Laura C. Michaelis, Megan Othus, Geoffrey L. Uy, Jerald P. Radich, Richard F. Little, Sandi Hita, Lalit Saini, James M. Foran, Aaron T. Gerds, Heidi D. Klepin, Annette E. Hay, Sarit Assouline, Jeffrey E. Lancet, Stephen Couban, Mark R. L Tags: Correspondence Source Type: research

Outcome of chronic lymphocytic leukemia patients who switched from either ibrutinib or idelalisib to alternate kinase inhibitor: A retrospective study of the French Innovative Leukemia Organization (FILO)
(Source: American Journal of Hematology)
Source: American Journal of Hematology - November 22, 2017 Category: Hematology Authors: Sophie Godet, Caroline Protin, Jehan Dupuis, Caroline Dartigeas, Jean ‐Noël Bastie, Charles Herbaux, Véronique Leblond, Sophie de Guibert, David Ghez, Annie Brion, Loïc Ysebaert, Alain Delmer, Anne Quinquenel Tags: Correspondence Source Type: research

Excess mortality among 10 ‐year survivors of classical Hodgkin lymphoma in adolescents and young adults
Abstract Adolescents and young adults (AYA) surviving classical Hodgkin lymphoma (cHL) risk long term fatal treatment‐related toxicities. We utilized the Surveillance, Epidemiology and End Results (SEER) program to compare excess mortality rate (EMR‐observed minus expected mortality) for 10‐year survivors of AYA cHL diagnosed in 1973–1992 and 1993–2003 eras. The 15‐year EMR reduced from 4.88% to 2.19% while the 20‐year EMR reduced from 9.46% to 4.07% between eras. Survivors of stages 1–2 had lower EMR than survivors of stages 3–4 cHL in the 1993‐2003 but not in the 1973–1992 era. T...
Source: American Journal of Hematology - November 21, 2017 Category: Hematology Authors: Ana C. Xavier, Narendranath Epperla, Jeffrey W. Taub, Luciano J. Costa Tags: RESEARCH ARTICLE Source Type: research

Sickle hemoglobin oxygen affinity ‐shifting strategies have unequal cerebrovascular risks
(Source: American Journal of Hematology)
Source: American Journal of Hematology - November 18, 2017 Category: Hematology Authors: Robert P. Hebbel, Bo E. Hedlund Tags: Commentary Source Type: research

Ruxolitinib ‐associated infections: a systematic review and meta‐analysis
This article is protected by copyright. All rights reserved. (Source: American Journal of Hematology)
Source: American Journal of Hematology - November 18, 2017 Category: Hematology Authors: Federico Lussana, Marco Cattaneo, Alessandro Rambaldi, Alessandro Squizzato Tags: Research Article Source Type: research

Impact of gene mutations on treatment response and prognosis of acute myeloid leukemia secondary to myeloproliferative neoplasms
Abstract Acute myeloid leukemias secondary (sAML) to myeloproliferative neoplasms (MPN) have variable clinical courses and outcomes, but remain almost always fatal. Large cohorts of sAML to MPN are difficult to obtain and there is very little scientific literature or prospective trials for determining robust prognostic markers and efficient treatments. We analyzed event‐free survival (EFS) and overall survival (OS) of 73 patients with MPN who progressed to sAML, based on their epidemiological characteristics, the preexisting MPN, the different treatments received, the different prognostic groups and the responses achieve...
Source: American Journal of Hematology - November 17, 2017 Category: Hematology Authors: G. Venton, F. Courtier, A. Charbonnier, E. D'Incan, C. Saillard, B. Mohty, MJ. Mozziconacci, D. Birnbaum, A. Murati, N. Vey, J. Rey Tags: Research Article Source Type: research

Characteristics of chronic lymphocytic leukemia patients achieving 5+ years of remission after FC ‐based first‐line treatment: Retrospective observations from the FILO group
(Source: American Journal of Hematology)
Source: American Journal of Hematology - November 17, 2017 Category: Hematology Authors: Yann Guillermin, Charles Herbaux, Fabien Subtil, Th érèse Aurran‐Schleinitz, Florence Cymbalista, Remi Letestu, Stéphane Leprêtre, Sandrine Vaudaux, Kamel Laribi, Véronique Leblond, Yasmina Defoi, Raouf Benchikh, Gilles Salles, Pascal Godmer, Henry Tags: CORRESPONDENCE Source Type: research

MYD88 mutation status does not impact overall survival in Waldenstr öm macroglobulinemia
In conclusion, MYD88L265P mutation does not appear to be a determinant of outcome, and its presence may not be a disease‐defining feature in WM. Our findings warrant external validation, preferably through prospective studies. (Source: American Journal of Hematology)
Source: American Journal of Hematology - November 17, 2017 Category: Hematology Authors: Jithma P. Abeykoon, Jonas Paludo, Rebecca L. King, Stephen M. Ansell, Morie A. Gertz, Betsy R. LaPlant, Alese E. Halvorson, Wilson I. Gonsalves, David Dingli, Hong Fang, S. Vincent Rajkumar, Martha Q. Lacy, Rong He, Taxiarchis Kourelis, Craig B. Reeder, A Tags: RESEARCH ARTICLE Source Type: research

Phase 1 Study of Quizartinib in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia
This article is protected by copyright. All rights reserved. (Source: American Journal of Hematology)
Source: American Journal of Hematology - November 15, 2017 Category: Hematology Authors: Jessica K. Altman, James M. Foran, Keith W. Pratz, Denise Trone, Jorge E. Cortes, Martin S. Tallman Tags: Research Article Source Type: research

Ruxolitinib as First ‐Line Treatment in Secondary Hemophagocytic Lymphohistiocytosis: A Single Patient Experience
(Source: American Journal of Hematology)
Source: American Journal of Hematology - November 14, 2017 Category: Hematology Authors: J. Slostad, P. Hoversten, C.L. Haddox, K. Cisak, J. Paludo, A. Tefferi Tags: Correspondence Source Type: research

A Phase II Trial of Ruxolitinib in Combination with Azacytidine in Myelodysplastic Syndrome/Myeloproliferative Neoplasms
This article is protected by copyright. All rights reserved. (Source: American Journal of Hematology)
Source: American Journal of Hematology - November 14, 2017 Category: Hematology Authors: Rita Assi, Hagop M. Kantarjian, Guillermo Garcia ‐Manero, Jorge E. Cortes, Naveen Pemmaraju, Xuemei Wang, Graciela Nogueras‐Gonzalez, Elias Jabbour, Prithviraj Bose, Tapan Kadia, Courtney D. Dinardo, Keyur Patel, Carlos Bueso‐Ramos, Lingsha Zhou, Sh Tags: Research Article Source Type: research

Identification of ceruloplasmin as a biomarker of chronic kidney disease in urine of sickle cell disease patients by proteomic analysis
(Source: American Journal of Hematology)
Source: American Journal of Hematology - November 11, 2017 Category: Hematology Authors: Marina Jerebtsova, Santosh L. Saraf, Xionghao Lin, Gillian Lee, Elena Afia Adjei, Namita Kumari, Nowah Afangbedji, Rasha Raslan, Charlee McLean, Victor R. Gordeuk, Sergei Nekhai Tags: Correspondence Source Type: research

A key role for Rac and Pak signaling in Neutrophil Extracellular Traps (NETs) formation defines a new potential therapeutic target
This article is protected by copyright. All rights reserved. (Source: American Journal of Hematology)
Source: American Journal of Hematology - November 10, 2017 Category: Hematology Authors: M Gavillet, K Martinod, R Renella, DD Wagner, DA Williams Tags: Research Article Source Type: research

MECOM, HBS1L ‐MYB, THRB‐RARB, JAK2, and TERT polymorphisms defining the genetic predisposition to myeloproliferative neoplasms: A study on 939 patients
In conclusion, JAK2 46/1, TERT rs2736100 and MECOM rs2201862 are the chief predisposing polymorphisms to MPN. (Source: American Journal of Hematology)
Source: American Journal of Hematology - November 10, 2017 Category: Hematology Authors: Adrian P. Trifa, Claudia B ănescu, Anca S. Bojan, Cristian M. Voina, Ștefana Popa, Simona Vișan, Alina D. Ciubean, Florin Tripon, Delia Dima, Viola M. Popov, Ștefan C. Vesa, Mihaela Andreescu, Tünde Török‐Vistai, Romeo G. Mihăilă, Nicoleta Berb Tags: RESEARCH ARTICLE Source Type: research

Safety and Efficacy of Early Start of Iron Chelation Therapy with Deferiprone in Young Children Newly Diagnosed with Transfusion ‐Dependent Thalassemia: A Randomized Controlled Trial
This study investigated whether deferiprone, a chelator with a lower affinity for iron than deferoxamine, could postpone transfusional iron overload while maintaining a good safety profile. Recently diagnosed TDT infants (N=64 their age ranged from10‐18 (median 12) months, 54.7% males; receiving 400‐ 1000 µg/L and TSAT > 70% compared with none in the ES‐DFP group. LPI level>0.6 µM was observed in 97% vs. 40% of the DS and ES groups, respectively, (p1000 µg/L was delayed by 6 months in the ES‐DFP group (P
Source: American Journal of Hematology - November 9, 2017 Category: Hematology Authors: Mohsen Saleh Elalfy, Amira Adly, Hanem Awad, Mohamed Tarif Salam, Vasilios Berdoukas, Fernando Tricta Tags: Research Article Source Type: research

Hispanic ethnicity as a risk factor for requiring glucarpidase rescue in pediatric patients receiving high ‐dose methotrexate
(Source: American Journal of Hematology)
Source: American Journal of Hematology - November 9, 2017 Category: Hematology Authors: Eric S. Schafer, M. Brooke Bernhardt, Kate E. Reichert, Tara E. Haworth, Mona D. Shah Tags: Correspondence Source Type: research

A Phase I Study of Lenalidomide plus Chemotherapy with Mitoxantrone, Etoposide, and Cytarabine for the Reinduction of Patients with Acute Myeloid Leukemia
This article is protected by copyright. All rights reserved. (Source: American Journal of Hematology)
Source: American Journal of Hematology - November 9, 2017 Category: Hematology Authors: Daniel J. DeAngelo, Andrew M. Brunner, Lillian Werner, David Avigan, Amir T. Fathi, Adam S. Sperling, Abigail Washington, Dina Stroopinsky, Jacalyn Rosenblatt, Malgorzata McMasters, Katarina Luptakova, Martha Wadleigh, David P. Steensma, Gabriela S. Hobbs Tags: Research Article Source Type: research

The Risk of Venous Thromboembolism in Patients with Clinically Overt Gastrointestinal Bleeding
(Source: American Journal of Hematology)
Source: American Journal of Hematology - November 9, 2017 Category: Hematology Authors: Mohammed Almakadi, Christopher Sheasgreen, Ahmed Barefah, Lucy Lu, Nidhi Kumar Tyagi, Gillian Mazzetti, Lindsay Crabbe, Yuhong Yuan, Mark Crowther, Grigorios Leontiadis Tags: Correspondence Source Type: research

Donor age determines outcome in acute leukemia patients over 40 undergoing haploidentical hematopoietic cell transplantation
This article is protected by copyright. All rights reserved. (Source: American Journal of Hematology)
Source: American Journal of Hematology - November 8, 2017 Category: Hematology Authors: Jonathan Canaani, Bipin N Savani, Myriam Labopin, Xiao ‐jun Huang, Fabio Ciceri, William Arcese, Yener Koc, Johanna Tischer, Didier Blaise, Zafer Gülbas, Maria Teresa Van Lint, Benedetto Bruno, Mohamad Mohty, Arnon Nagler Tags: Research Article Source Type: research

Excess Mortality Among Ten ‐Year Survivors of Classical Hodgkin Lymphoma in Adolescents and Young Adults
This article is protected by copyright. All rights reserved. (Source: American Journal of Hematology)
Source: American Journal of Hematology - November 8, 2017 Category: Hematology Authors: Ana C. Xavier, Narendranath Epperla, Jeffrey W. Taub, Luciano J. Costa Tags: Research Article Source Type: research

Hairy cell leukemia 2018: Update on diagnosis, risk ‐stratification, and treatment
Abstract Disease overviewHairy cell leukemia (HCL) and HCL‐like disorders, including HCL variant (HCL‐V) and splenic diffuse red pulp lymphoma (SDRPL), are a very heterogeneous group of mature lymphoid B‐cell disorders, characterized by the identification of hairy cells, a specific genetic profile, a different clinical course and the need for appropriate treatment. DiagnosisDiagnosis of HCL is based on morphological evidence of hairy cells, an HCL immunologic score of 3 or 4 based on the CD11C, CD103, CD123, and CD25 expression, the trephine biopsy which makes it possible to specify the degree of tumoral medullary in...
Source: American Journal of Hematology - November 7, 2017 Category: Hematology Authors: Xavier Troussard, Edouard Cornet Tags: ANNUAL CLINICAL UPDATES IN HEMATOLOGICAL MALIGNANCIES Source Type: research

Issue Information – Table of Contents
(Source: American Journal of Hematology)
Source: American Journal of Hematology - November 7, 2017 Category: Hematology Tags: ISSUE INFORMATION – TABLE OF CONTENTS Source Type: research

Therapy related ‐chronic myelomonocytic leukemia (CMML): Molecular, cytogenetic, and clinical distinctions from de novo CMML
Abstract Therapy related myeloid neoplasms (t‐MN) including therapy related myelodysplastic syndromes (t‐MDS) and acute myeloid leukemia (t‐AML) are associated with aggressive disease biologies and poor outcomes. In this large (n = 497) and informative (inclusive of molecular and cytogenetic information) chronic myelomonocytic leukemia (CMML) patient cohort, we demonstrate key biological insights and an independent prognostic impact for t‐CMML. T‐CMML was diagnosed in 9% of patients and occurred approximately 7 years after exposure to prior chemotherapy and/or radiation therapy. In comparison to de ...
Source: American Journal of Hematology - November 3, 2017 Category: Hematology Authors: Mrinal M. Patnaik, Rangit Vallapureddy, Fevzi F. Yalniz, Curtis A. Hanson, Rhett P. Ketterling, Terra L. Lasho, Christy Finke, Aref Al ‐Kali, Naseema Gangat, Ayalew Tefferi Tags: RESEARCH ARTICLE Source Type: research